We conclude that CML LT-HSCs expressing low c-KIT levels are enriched for primitive, quiescent, drug-resistant leukemia-initiating cells and represent a critical target for eliminating disease persistence. Here, KIT is linked to chronic myelogenous leukemia, BCR-ABL1 positive.